SCHEMBL5355226

SCHEMBL5355226

CN(C)/C=C(\C(=O)c1cccc(F)c1)c1ccnc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TP53 P04637 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
CDK9 P50750 1/20 0.37
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
GSK3B P49841 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
NR3C2 P08235 1/20 0.35
CYP17A1 P05093 2/20 0.35
GSK3A P49840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355228 1.00 NPC1 (0.37) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL5357992 0.89 HTR1F (0.39) NPC1RAB9ASMN1; SMN2TP53GSK3B
SCHEMBL5357995 0.89 HTR1F (0.39) NPC1RAB9ASMN1; SMN2TP53GSK3B
SCHEMBL5351320 0.89 ACACB (0.39) NPC1RAB9AGSK3BIRAK4NR3C2
SCHEMBL5351318 0.89 ACACB (0.39) NPC1RAB9AGSK3BIRAK4NR3C2
SCHEMBL5347562 0.89 NPSR1 (0.41) CES2NR3C2
SCHEMBL5347559 0.89 NPSR1 (0.41) CES2NR3C2
SCHEMBL5356757 0.87 CYP17A1 (0.39) CES2CES1GSK3BIRAK4CYP17A1
SCHEMBL5356752 0.87 CYP17A1 (0.39) CES2CES1GSK3BIRAK4CYP17A1
SCHEMBL5348696 0.85 CYP11B1 (0.38) GSK3BIRAK4CYP17A1SYKCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553096-B1 PYRAZOLE COMPOUNDS UBE INDUSTRIES (JP) 2012-10-31 EP disclosed
US-7294625-B2 Pyrazole compounds UBE INDUSTRIES, LTD. (JP) 2007-11-13 US disclosed
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis UBE INDUSTRIES, LTD. (JP) 2006-03-23 US disclosed
EP-1553096-A1 PYRAZOLE COMPOUNDS Ube Industries, Ltd. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis CNKSR1, MAPK1, MAPK3 NPC1 4466/4885RAB9A 469/4885SMN1; SMN2 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.